ArticleCancer research communications2025
Inhibition of Extracellular Matrix Protein Fibulin-3 Reduces Immunosuppressive Signaling and Increases Macrophage Activation in Glioblastoma.
Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma.bioRxiv : the preprint server for biology · 2026Article
- Neurosurgery as an immune anchor point: a translational framework for perioperative immunoengineering.Frontiers in immunology · 2026Review
- A brain cancer microtissue model for studying tumor cell and neural cell interactions.Scientific reports · 2025Article
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
Glioblastoma (GBM) tumors remain a challenge for immunotherapy owing to their heterogeneous and immunologically cold properties. GBM cells change the composition of the neural extracellular matrix (ECM), affecting the mobility, survival, and function of immune cells such as tumor-associated microglia and infiltrated macrophages (TAM). The ECM protein fibulin-3/EFEMP1 is a pericellular component uniquely upregulated in GBM compared with the normal brain, which promotes tumor growth and invasion. In this study, we demonstrate that fibulin-3 indirectly modulates TAM behavior and can be targeted to restore innate immune responses. Intracranial tumors initiated by fibulin-3-deficient GBM cells showed increased presence of TAMs with decreased immunosuppression markers (arginase-1, CD206), whereas the opposite effects were observed in tumors overexpressing fibulin-3. In silico analyses revealed a positive correlation between fibulin-3 and an immunosuppressive signature that was validated in GBM stem cells and in vivo. We further demonstrated that fibulin-3 regulates the expression of immunosuppressive signals (CSF-1, TGF-β1, and CD47) by autocrine activation of NF-κB signaling. Immunosuppressive signals were downregulated by knockdown of fibulin-3 in GBM stem cells and by inhibition of this protein using an anti-fibulin-3 antibody. Myeloid cells exhibited higher phagocytic activity and killing of GBM cells in presence of this antibody. Furthermore, locoregional delivery of anti-fibulin-3 in mice with intracranial GBM increased the presence of proinflammatory TAMs, thereby reducing tumor viability. Our findings show that anti-fibulin-3 approaches, which affect the ECM surrounding tumor and immune cells, can diminish immunosuppression in GBM and boost innate immune responses against the tumor. SIGNIFICANCE: Inhibition of the ECM protein fibulin-3, which is highly upregulated in glioblastoma tumors, decreases immunosuppressive signals produced by the tumor cells and exposes them to increased attack by TAMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.